WealthTrust Axiom’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.32M | Sell |
42,122
-250
| -0.6% | -$32.9K | 1.19% | 19 |
|
|
2026
Q1 | $5.91M | Sell |
42,372
-425
| -1% | -$59.5K | 1.45% | 18 |
|
|
2025
Q4 | $5.25M | Sell |
42,797
-802
| -2% | -$97.5K | 1.35% | 20 |
|
|
2025
Q3 | $4.84M | Sell |
43,599
-975
| -2% | -$111K | 1.3% | 20 |
|
|
2025
Q2 | $4.94M | Sell |
44,574
-6,258
| -12% | -$666K | 1.45% | 19 |
|
|
2025
Q1 | $5.7M | Sell |
50,832
-1,020
| -2% | -$105K | 1.73% | 11 |
|
|
2024
Q4 | $4.79M | Sell |
51,852
-713
| -1% | -$64.2K | 1.43% | 18 |
|
|
2024
Q3 | $4.41M | Sell |
52,565
-518
| -1% | -$39.5K | 1.31% | 20 |
|
|
2024
Q2 | $3.64M | Sell |
53,083
-693
| -1% | -$46.2K | 1.21% | 22 |
|
|
2024
Q1 | $3.94M | Sell |
53,776
-1,254
| -2% | -$96.4K | 1.27% | 18 |
|
|
2023
Q4 | $4.46M | Buy |
55,030
+132
| +0.2% | +$10.3K | 1.49% | 16 |
|
|
2023
Q3 | $4.11M | Sell |
54,898
-638
| -1% | -$49.1K | 1.48% | 15 |
|
|
2023
Q2 | $4.28M | Buy |
55,536
+2
| +0% | +$160 | 1.42% | 17 |
|
|
2023
Q1 | $4.61M | Sell |
55,534
-780
| -1% | -$64.6K | 1.57% | 16 |
|
|
2022
Q4 | $4.83M | Sell |
56,314
-3,033
| -5% | -$240K | 1.69% | 14 |
|
|
2022
Q3 | $3.66M | Buy |
59,347
+612
| +1% | +$38.6K | 1.4% | 18 |
|
|
2022
Q2 | $3.63M | Sell |
58,735
-791
| -1% | -$49K | 1.29% | 19 |
|
|
2022
Q1 | $3.54M | Buy |
59,526
+131
| +0.2% | +$8.37K | 1.11% | 22 |
|
|
2021
Q4 | $4.31M | Sell |
59,395
-604
| -1% | -$41.6K | 1.38% | 16 |
|
|
2021
Q3 | $4.19M | Buy |
59,999
+579
| +1% | +$40.7K | 1.42% | 17 |
|
|
2021
Q2 | $4.09M | Buy |
59,420
+9,234
| +18% | +$617K | 1.31% | 20 |
|
|
2021
Q1 | $3.24M | Buy |
50,186
+11,200
| +29% | +$722K | 1.1% | 28 |
|
|
2020
Q4 | $2.27M | Sell |
38,986
-2,424
| -6% | -$146K | 0.83% | 31 |
|
|
2020
Q3 | $2.62M | Sell |
41,410
-13,359
| -24% | -$926K | 1.13% | 24 |
|
|
2020
Q2 | $4.21M | Buy |
54,769
+792
| +1% | +$60.7K | 1.85% | 15 |
|
|
2020
Q1 | $4.04M | Buy |
53,977
+2,508
| +5% | +$173K | 1.98% | 14 |
|
|
2019
Q4 | $3.34M | Buy |
51,469
+22,970
| +81% | +$1.5M | 1.12% | 27 |
|
|
2019
Q3 | $1.81M | Sell |
28,499
-353
| -1% | -$23.1K | 0.64% | 44 |
|
|
2019
Q2 | $1.95M | Buy |
28,852
+7,211
| +33% | +$474K | 0.68% | 41 |
|
|
2019
Q1 | $1.41M | Buy |
21,641
+1,937
| +10% | +$129K | 0.5% | 56 |
|
|
2018
Q4 | $1.23M | Sell |
19,704
-665
| -3% | -$46.5K | 0.5% | 58 |
|
|
2018
Q3 | $1.57M | Buy |
20,369
+355
| +2% | +$26.8K | 0.53% | 53 |
|
|
2018
Q2 | $1.42M | Sell |
20,014
-38
| -0.2% | -$2.68K | 0.5% | 51 |
|
|
2018
Q1 | $1.51M | Buy |
20,052
+735
| +4% | +$58.4K | 0.55% | 54 |
|
|
2017
Q4 | $1.38M | Sell |
19,317
-385
| -2% | -$29.2K | 0.51% | 56 |
|
|
2017
Q3 | $1.6M | Buy |
19,702
+192
| +1% | +$14.7K | 0.61% | 49 |
|
|
2017
Q2 | $1.38M | Sell |
19,510
-31
| -0.2% | -$2.06K | 0.52% | 54 |
|
|
2017
Q1 | $1.33M | Buy |
19,541
+3,303
| +20% | +$232K | 0.49% | 56 |
|
|
2016
Q4 | $1.16M | Sell |
16,238
-416
| -2% | -$30.9K | 0.42% | 65 |
|
|
2016
Q3 | $1.32M | Buy |
16,654
+8,042
| +93% | +$653K | 0.49% | 59 |
|
|
2016
Q2 | $718K | Buy |
8,612
+320
| +4% | +$28.4K | 0.28% | 88 |
|
|
2016
Q1 | $761K | Buy |
8,292
+421
| +5% | +$38K | 0.3% | 82 |
|
|
2015
Q4 | $796K | Buy |
7,871
+5,649
| +254% | +$588K | 0.32% | 79 |
|
|
2015
Q3 | $218K | Buy |
+2,222
| New | +$247K | 0.09% | 173 |
|
Other funds holding GILD
WealthTrust Axiom's GILD Position: Q2 2026 in Review
WealthTrust Axiom reduced its Gilead Sciences (GILD) stake by 0.59% in Q2 2026, selling an estimated $32.9K and leaving 42,122 shares worth $5.32M. The position accounts for 1.19% of the portfolio, ranked #19.
WealthTrust Axiom first reported a position in GILD in Q3 2015 and has held it in 44 quarters since. The position peaked at $5.91M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- WealthTrust Axiom held 42,122 shares of Gilead Sciences worth $5.32M as of Q2 2026.
- WealthTrust Axiom sold 250 Gilead Sciences shares in Q2 2026, an estimated $32.9K.
- Gilead Sciences made up 1.19% of WealthTrust Axiom's portfolio in Q2 2026, its #19 holding.
- WealthTrust Axiom first reported a position in Gilead Sciences in Q3 2015 and has held it in 44 quarters since.
- WealthTrust Axiom's Gilead Sciences position peaked at $5.91M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on WealthTrust Axiom's 13F filing for Q2 2026, filed 11 Aug 2026.